• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

NeoRx settles investor lawsuits

Article

Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination

Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination of stock and cash worth $1.5 million. A substantialportion of the settlement will be covered by insurance, the companysaid.

NeoRx last month also reported its financial results for 1994(end-December). The company reported a net loss of $11.1 millionon revenues of $1.6 million for the year, compared to a net lossof $8.5 million and revenues of $3.7 million in 1993.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC

Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC

Jeff Hall
February 11th 2025
Article

A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 3

Jeff Hall
September 1st 2023
Podcast

In the third episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss the challenges of expanded breast cancer screening amid a backdrop of radiologist shortages and ever-increasing volume on radiology worklists.

Breast MRI and Ultrasound Findings Linked to Elevated Risk of Axillary Residual Disease After Neoadjuvant Therapy

Breast MRI and Ultrasound Findings Linked to Elevated Risk of Axillary Residual Disease After Neoadjuvant Therapy

Jeff Hall
February 10th 2025
Article

Anterior tumor location was over 14 times more likely to be associated with axillary metastasis after neoadjuvant treatment for breast cancer, according to new breast MRI and ultrasound research.

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 2

The Reading Room Podcast: Emerging Concepts in Breast Cancer Screening and Health Equity Implications, Part 2

Jeff Hall
August 23rd 2023
Podcast

In the second episode of a three-part podcast, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recent studies published by the Journal of the American Medical Association (JAMA) that suggested moving to more of a risk-adapted model for mammography screening.

Ultrasound Molecular Agent Gets FDA Fast Track Designation for Active Bowel Inflammation with Crohn’s Disease

Ultrasound Molecular Agent Gets FDA Fast Track Designation for Active Bowel Inflammation with Crohn’s Disease

Jeff Hall
February 7th 2025
Article

Phase 2 studies of the BR55 ultrasound contrast agent reportedly demonstrated a 95 percent accuracy in showing the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in bowel segments reflecting active inflammation in patients with Crohn’s disease.

Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection

Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection

Jeff Hall
February 6th 2025
Article

The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).

© 2025 MJH Life Sciences

All rights reserved.